Literature DB >> 3780475

Effect of non-steroidal anti-inflammatory drugs on the human small intestine.

I Bjarnason, G Zanelli, P Prouse, P Williams, M J Gumpel, A J Levi.   

Abstract

The suggestion that the intestinal mucosa may be abnormally permeable and thus a site of antigen absorption in rheumatoid arthritis was tested by a 51Cr EDTA intestinal permeability test. Twelve patients with rheumatoid arthritis untreated by non-steroidal anti-inflammatory drugs (NSAIDs) had normal test results, while 12 NSAID-treated patients had increased intestinal permeability. Ten volunteers ingested aspirin, ibuprofen and indomethacin 8 and 1 hours before the study. The increased intestinal permeability was proportional to drug potency to inhibit cyclo-oxygenase. Intestinal permeability also increased following an indomethacin suppository, which suggests that the effect is systemically mediated. 111Indium leucocyte scintigrams and faecal collection showed no evidence of intestinal inflammation in 9 patients untreated by NSAIDs. Twenty-nine of 53 NSAID-treated patients showed abnormal localisation of 111indium in the right iliac fossa at 20 hours, and 32 of 49 patients had increased faecal excretion of 111indium. A 99mTc-porphyrin scan suggested that the main site of NSAID-induced intestinal inflammation was the small bowel. NSAIDs are thus shown to disrupt intestinal integrity and long term treatment leads to inflammation of the small intestine.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3780475     DOI: 10.2165/00003495-198600321-00007

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  20 in total

1.  Technetium-99m labelled porphyrin as an imaging agent for occult infections and inflammation.

Authors:  G D Zanelli; I Bjarnason; T Smith; J C Crawley; A J Levi; R I Copeland
Journal:  Nucl Med Commun       Date:  1986-01       Impact factor: 1.690

Review 2.  Uptake and transport of macromolecules by the intestine. Possible role in clinical disorders.

Authors:  W A Walker; K J Isselbacher
Journal:  Gastroenterology       Date:  1974-09       Impact factor: 22.682

3.  Effect of fasting and lactovegetarian diet on rheumatoid arthritis.

Authors:  L Sköldstam; L Larsson; F D Lindström
Journal:  Scand J Rheumatol       Date:  1979       Impact factor: 3.641

4.  Role of bacteria in gastric ulceration produced by indomethacin in the rat: cytoprotective action of antibiotics.

Authors:  H Satoh; P H Guth; M I Grossman
Journal:  Gastroenterology       Date:  1983-03       Impact factor: 22.682

5.  Resistance of germfree rats to indomethacin-induced intestinal lesions.

Authors:  A Robert; T Asano
Journal:  Prostaglandins       Date:  1977-08

Review 6.  Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms.

Authors:  T A Miller
Journal:  Am J Physiol       Date:  1983-11

7.  Intestinal permeability and inflammation in rheumatoid arthritis: effects of non-steroidal anti-inflammatory drugs.

Authors:  I Bjarnason; P Williams; A So; G D Zanelli; A J Levi; J M Gumpel; T J Peters; B Ansell
Journal:  Lancet       Date:  1984-11-24       Impact factor: 79.321

8.  Absorption of 51chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease.

Authors:  I Bjarnason; C O'Morain; A J Levi; T J Peters
Journal:  Gastroenterology       Date:  1983-08       Impact factor: 22.682

9.  Intestinal permeability in patients with coeliac disease and dermatitis herpetiformis.

Authors:  I Bjarnason; M N Marsh; A Price; A J Levi; T J Peters
Journal:  Gut       Date:  1985-11       Impact factor: 23.059

10.  Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat.

Authors:  B J Whittle
Journal:  Gastroenterology       Date:  1981-01       Impact factor: 22.682

View more
  9 in total

1.  Multiple enterocolic perforations and their possible association with prolonged intake of nimesulide: report of two cases.

Authors:  Corrado Rosario Asteria; Giacomo Batignani; Alessandro Garcea; Francesco Tonelli
Journal:  Dig Dis Sci       Date:  2005-09       Impact factor: 3.199

2.  Do non-steroidal anti-inflammatory drugs increase colonic permeability?

Authors:  A P Jenkins; D R Trew; B J Crump; W S Nukajam; J A Foley; I S Menzies; B Creamer
Journal:  Gut       Date:  1991-01       Impact factor: 23.059

3.  Influence of prolonged exposure of a short half life non-steroidal anti-inflammatory drugs on gastrointestinal safety.

Authors:  Corinne Campanella; Fakhreddin Jamali
Journal:  Inflammopharmacology       Date:  2009-07-08       Impact factor: 4.473

4.  Ileocaecal perforation and bleeding--are non-steroidal anti-inflammatory drugs (NSAIDs) responsible?

Authors:  K C Saw; C R Quick; A F Higgins
Journal:  J R Soc Med       Date:  1990-02       Impact factor: 5.344

5.  Long-term follow-up of nonspecific small bowel ulcers with a benign course and no requirement for surgery: is this a distinct group?

Authors:  Weifeng Wang; Zhanbo Wang; Yunsheng Yang; Enqiang Linghu; Zhongsheng Lu
Journal:  BMC Gastroenterol       Date:  2011-05-10       Impact factor: 3.067

Review 6.  Differences in NSAID tolerability profiles. Fact or fiction?

Authors:  K J Skeith; M Wright; P Davis
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

Review 7.  Nonsteroidal anti-inflammatory drug-induced gastrointestinal toxicity: new insights into an old problem.

Authors:  N M Davies; J L Wallace
Journal:  J Gastroenterol       Date:  1997-02       Impact factor: 7.527

Review 8.  Determining small bowel integrity following drug treatment.

Authors:  Simon Smale; Ingvar Bjarnason
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

9.  Lack of effects of acemetacin on signalling pathways for leukocyte adherence may explain its gastrointestinal safety.

Authors:  A E Chávez-Piña; L Vong; W McKnight; M Dicay; R C O Zanardo; M I Ortiz; G Castañeda-Hernández; J L Wallace
Journal:  Br J Pharmacol       Date:  2008-08-11       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.